Recruiting

Observational Study

Sponsor:

Insmed Incorporated

Code:

NCT07948772

Conditions

Ataxia Telangiectasia

Eligibility Criteria

Sex: All

Age: 1 - 10

Healthy Volunteers: Accepted

Study Details

Brief summary:

The primary objective of this study is to assess the natural history of AT symptoms and disease progression over time in children aged 1 to 10 years old diagnosed with classic AT.

Conditions

Ataxia Telangiectasia

Study ID

NCT07948772

Start date

Jun 30, 2026

Status verified date

Nov, 2026

Completion date

May 30, 2029

Anticipated

Primary completion date

May 30, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 1 - 10

Healthy Volunteers: Accepted

Inclusion Criteria for the AT Cohort:

  • Diagnosis of classic AT based on investigator's assessment of clinical presentation and genotyping.
  • If three years to 10 years (<11 years) old, the primary caregiver has self-reported to the site that the participant with AT can walk approximately 33 feet (10 meters) without support from a helper, and without the use of a walking aid.
  • Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver informed consent form.

Inclusion Criteria for the Healthy Comparator Cohort:

  • Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver consent form.

Exclusion Criteria for the AT Cohort:

  • Participation in a clinical trial of a candidate therapeutic for AT, with last administration of a candidate therapeutic within 30 days or five half-lives (whichever is longer) preceding study baseline (start of data collection). For clarity, ongoing clinical trial participation that does not involve a therapeutic drug is acceptable. An exception to this exclusion is that up to approximately 20 participants receiving levacetylleucine (marketed as AQNEURSA®) in investigational trials, expanded access programs, or as a licensed drug are eligible.
  • Previous treatment with a chemotherapeutic agent for cancer.
  • Diagnosis of a condition other than AT that, in the opinion of the investigator, would compromise AT symptom measurement or current study participation.

Exclusion Criteria for the Healthy Comparator Cohort:

  • Diagnosis of any form of AT.
  • Previous treatment with a chemotherapeutic agent for cancer.
  • Diagnosis of a condition that, in the opinion of the investigator, would compromise the measurement of movement by wearable devices to serve as healthy comparators to AT participants.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Study Design

Enrollment

69 participants

Anticipated

Interventions and Outcome Measures

Arms

AT Cohort

Participants with confirmed AT at screening visit will be enrolled and followed for 24 months.

Healthy Comparator Cohort

Participants without diagnosis of AT at screening visit will be enrolled and followed for 24 months.

Primary outcome measure

  • AT Cohort: Change From Baseline in AT Neurological Examination Scale Toolkit (A-TNEST) Score [ Time Frame: Baseline up to Month 24 ]
  • AT Cohort: Change From Baseline in International Cooperative Ataxia Rating Scale (ICARS) Score [ Time Frame: Baseline up to Month 24 ]

Central Contacts and Locations

Central contacts

Locations

USA002

Recruiting

Baltimore, Maryland, United States, 21287-0005

USA001

Recruiting

Boston, Massachusetts, United States, 02114

USA003

Recruiting

Houston, Texas, United States, 77030-3008

More Information

Sponsor

Insmed Incorporated

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • Ataxia Telangiectasia (AT or A-T)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Insmed Incorporated on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.